C（3〜6か月） Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> Cre/loxP system true Alexei Morozov Alexei Morozov 条件を付加する。<br>a) In all RECIPIENT publications related to the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature designated by the DEPOSITOR is requested:<br>J Neurosci. 2008 Feb 27;28(9):2089-98.Enhanced cortico-amygdala efficacy and suppressed fear in absence of Rap1. Pan BX, Vautier F, Ito W, Bolshakov VY, Morozov A.<br>b) In all publications or presentations of any research results obtained by use of the BIOLOGICAL RESOURCE, RECIPIENT will acknowledge the DEPOSITOR as the source of the BIOLOGICAL RESOURCE. <br>c) Use of the BIOLOGICAL RESOURCE for commercial purposes will require a license agreement between NIH and RECIPIENT. Information can be obtained at https://www.ott.nih.gov./.<br>d) Prior to filing an application for a patent, or intellectual property or other rights based on the use of the BIOLOGICAL RESOURCE, RECIPIENT will first notify the DEPOSITOR.<br>e) RECIPIENT agrees not to claim, infer, or imply endorsement by the DEPOSITOR.<br>f) Unless prohibited by law from doing so, RECIPIENT agrees to hold the DEPOSITOR harmless and to indemnify the DEPOSITOR for all liabilities, demands, damages, expenses and losses arising out of RECIPIENT 's use for any purpose of the BIOLOGICAL RESOURCE.<br>g) This BIOLOGICAL RESOURCE is provided as a service to the research community. IT IS BEING SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. RECIPIENT acknowledges that DEPOSITOR makes no representations that the use of the BIOLOGICAL RESOURCE will not infringe any patent or proprietary rights of third parties. <a href='https://brc.riken.jp/mus/pcr04720'>Genotyping protocol -PCR-</a> National Institute of Mental Health・Dr. Alexei Morozov. mouse Rapla genomic DNA, mouse Raplb genomic DNA, herpers simplex thymidine kinase promoter, E. coli Neomycin resistance gene, Bacteriophage P1 loxP site National Institute of Mental Health・Alexei Morozov.Developed by Alexei Morozov, National Institute of Mental Health. 129 ES cell derived. The mice were crossed to C57BL/6. Rap1a : Homozygote x Homozygote ; Rap1b : Homozygote x Homozygote [or Crossing to C57BL/6NCrlCrlj] Rap1a : Homozygote x Homozygote ; Rap1b : Homozygote x Homozygote [or Crossing to C57BL/6NCrlCrlj] a) In all RECIPIENT publications related to the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature designated by the DEPOSITOR is requested:<br>J Neurosci. 2008 Feb 27;28(9):2089-98.Enhanced cortico-amygdala efficacy and suppressed fear in absence of Rap1. Pan BX, Vautier F, Ito W, Bolshakov VY, Morozov A.<br>b) In all publications or presentations of any research results obtained by use of the BIOLOGICAL RESOURCE, RECIPIENT will acknowledge the DEPOSITOR as the source of the BIOLOGICAL RESOURCE. <br>c) Use of the BIOLOGICAL RESOURCE for commercial purposes will require a license agreement between NIH and RECIPIENT. Information can be obtained at https://www.ott.nih.gov./.<br>d) Prior to filing an application for a patent, or intellectual property or other rights based on the use of the BIOLOGICAL RESOURCE, RECIPIENT will first notify the DEPOSITOR.<br>e) RECIPIENT agrees not to claim, infer, or imply endorsement by the DEPOSITOR.<br>f) Unless prohibited by law from doing so, RECIPIENT agrees to hold the DEPOSITOR harmless and to indemnify the DEPOSITOR for all liabilities, demands, damages, expenses and losses arising out of RECIPIENT 's use for any purpose of the BIOLOGICAL RESOURCE.<br>g) This BIOLOGICAL RESOURCE is provided as a service to the research community. IT IS BEING SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. RECIPIENT acknowledges that DEPOSITOR makes no representations that the use of the BIOLOGICAL RESOURCE will not infringe any patent or proprietary rights of third parties. B6-Rap1a/Rap1b floxed B6-Rap1a/Rap1b floxed B6;129S-Rap1a<tm1Morz> Rap1b<tm1Morz> B6;129S-Rap1a<tm1Morz> Rap1b<tm1Morz> Rap1a and Rap1b floxed mice. Exons 2-3 of Rap1a gene and exon 1 of Rap1b gene were flanked by loxP sites. C (3-6 months) RBRC04720 Rap1a/Rap1b遺伝子のfloxedマウス。Rap1a遺伝子のエクソン2-3とRap1b遺伝子のエクソン1がloxPで挟まれている。